BeiGene (BGNE) experienced a significant surge in its stock price, soaring 5.37% in the 24-hour period leading up to Friday's trading session. This remarkable increase followed the announcement that four of the company's drugs were included in China's national medical insurance catalog.
According to a filing with the Shanghai Stock Exchange on Friday, China's medical products administrator has approved the inclusion of BeiGene's Tislelizumab and Zebutinib for tumors, Baituowei for prostate and breast cancer, and Carfilzomib for myeloma in the national medical insurance catalog. This pivotal decision means that these drugs will now be covered under the country's healthcare system, potentially increasing their accessibility and affordability for patients.
The news was well-received by investors, as BeiGene's shares rose 5% in Hong Kong and 3% in Shanghai during Friday's trading session. Analysts view this development as a significant milestone for the biopharmaceutical company, as it solidifies its position in the Chinese market and opens up new avenues for revenue growth through increased sales of these four drugs.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。